Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galderma Pharma has signed an agreement with Zars Pharma pursuant to which, Galderma gains exclusive rights for all markets outside the US and Canada for promotion and distribution of a novel topical anesthetic cream, Pliaglis.
Subscribe to our email newsletter
This partnership follows an agreement signed in 2007 between Galderma and Zars Pharma for the promotion and distribution of Pliaglis in the US and Canada.
Humberto Antunes, CEO of Galderma, said: “This agreement is part of our strategy to offer a comprehensive range of products that improve corrective and aesthetic procedural outcomes and complement our current family of therapeutic Rx and OTC products throughout the world.”